BioShares Biotechnology Buy or Sell Recommendation

Macroaxis provides BioShares Biotechnology Clinical Trials buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BioShares Biotechnology positions. The advice algorithm takes into account all of BioShares Biotechnology Clinical Trials available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from BioShares Biotechnology buy-and-hold prospective. Check also BioShares Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus

Time Horizon

Risk Tolerance

Symbol
Execute Advice
BioShares Biotechnology Clinical Trials -- USA Etf  

USD 30.6  0.75  2.51%

Considering 30-days investment horizon, and your above average risk tolerance our recommendation regarding BioShares Biotechnology Clinical Trials is 'Sell'.
For the selected time horizon BioShares Biotechnology Clinical Trials has a mean deviation of 1.26, semi deviation of 1.23, standard deviation of 1.67, variance of 2.79, downside variance of 3.47 and semi variance of 1.5
Macroaxis buy, hold, or sell suggestion module can be used to complement BioShares Biotechnology buy, hold, or sell recommendation provided by average analyst sentiment. It analyzes the etf potential to grow using fundamental, technical, data market data available at the time. Please makes use of BioShares Biotechnology Number of Employees as well as the relationship between One Year Return and Net Asset to make buy, hold, or sell decision on BioShares Biotechnology.

Returns Distribution Density

Mean Return0.54Value At Risk2.01
Potential Upside2.79Standard Deviation1.67
 Return Density 
      Distribution 

BioShares Biotechnology Greeks

α
Alpha over DOW
=1.02
β
Beta against DOW=2.34
σ
Overall volatility
=1.75
Ir
Information ratio =0.19

BioShares Biotechnology Volatility Alert

BioShares Biotechnology Clinical Trials has relatively low volatility with skewness of -0.55 and kurtosis of 0.34. However, we advise all investors to independently investigate BioShares Biotechnology Clinical Trials to ensure market all accessible information is consistent with the expectations about its upside potential and future risk-adjusted return.
    
 Better Than Average     
    
 Worse Than Average Compare BioShares Biotechnology to competition
FundamentalsBioShares BiotechnologyPeer Average
Price to Earning39.87 times8.24 times
Price to Book1.75 times0.97 times
Price to Sales1.99 times0.72 times
One Year Return56.1 % (1.25) %
Three Year Return1.36 % 2.26 %
Net Asset31.18 M888.73 M
Equity Positions Weight100 % 49.22 %
SellBuy
Sell

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Currently Unavailable

Piotroski F Score

Financial Leverage

Inapplicable
Risk Adjusted Performance0.1341
Market Risk Adjusted Performance(0.22)
Mean Deviation1.26
Semi Deviation1.23
Downside Deviation1.86
Coefficient Of Variation310.15
Standard Deviation1.67
Variance2.79
Information Ratio0.1914
Jensen Alpha1.02
Total Risk Alpha(0.36)
Sortino Ratio0.1717
Treynor Ratio(0.23)
Maximum Drawdown6.65
Value At Risk(2.01)
Potential Upside2.79
Downside Variance3.47
Semi Variance1.5
Expected Short fall(1.47)
Skewness(0.55)
Kurtosis0.341